Vitality Biopharma, Inc. engages in unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. It operates through Pharmaceutical Operations and Clinical Operations segments. The Clinical Operations segment focuses on treating patients suffering from addiction and dependency. The Pharmaceutical Operations segment engages in research and development primarily related to the Company's cannabinoid pharmaceuticals. The company was founded by Avtar S. Dhillon and Robert T. Brooke on June 29, 2007 and is headquartered in Los Angeles, CA.
Our net loss during the three months ended June 30, 2019 was $1,591,279 compared to a net loss of $1,135,219 for the three months ended June 30, 2018. Included in net loss during the three months ended June 30, 2019, our discontinued operations incurred a loss of $450,027, compared to a loss of $55,695 in the 2018 period. We had no revenue from continuing operations during either the 2019 or 2018 period.
During the three months ended June 30, 2019, we incurred general and administrative expenses in the aggregate amount of $852,419 compared to $480,701 incurred during the three months ended June 30, 2018 (an increase of $371,718). General and administrative expenses generally include corporate overhead, salaries and other compensation costs, financial and administrative contracted services, marketing, consulting costs and travel expenses. The majority of the increase in general and administrative costs in the period relates to legal fees which increased to $270,875 in the period ending June 30, 2019, as compared to $82,943 in the period ending June 30, 2018.
In addition, during the three months ended June 30, 2019, we incurred research and development costs of $328,488, compared to $573,630 during the three months ended June 30, 2018 (a decrease of $245,142). This decrease resulted from decreased consulting expenses during the 2019 period.